Alcobra Ltd. (ADHD) - NASDAQ
  • Mon, May 16, 9:30 AM
    • Alcobra (ADHD) Q1 results: Revenues: $0; R&D Expense: $3.4M (-5.6%); SG&A: $1.5M (+15.4%); Net Loss: ($5.1M) (+1.9%); Loss Per Share: ($0.18) (+30.8%); Quick Assets: $53.2M (+4.9%); CF Ops: ($4.4M) (+4.3%).
    • No guidance given.
    | Mon, May 16, 9:30 AM
  • Mon, May 16, 8:04 AM
    • Alcobra (NASDAQ:ADHD): Q1 EPS of -$0.18 beats by $0.04.
    • Cash and cash equivalents of $13.5M
    • Press Release
    | Mon, May 16, 8:04 AM
  • Wed, Feb. 17, 10:03 AM
    • Alcobra (ADHD +2.2%) Q4 results: Revenues: $0; R&D Expense: $3.3M (-32.7%); SG&A: $1.3M (-7.1%); Net Loss: ($4.9M) (+27.9%); Loss Per Share: ($0.20) (+60.0%).
    • FY2015 results: Revenues: $0; R&D Expense: $13.5M (-46.2%); SG&A: $5M (-13.8%); Net Loss: ($19.4M) (+40.9%); Loss Per Share: ($0.90) (+62.5%); Quick Assets: $40.7M (+87.6%).
    • No guidance given.
    | Wed, Feb. 17, 10:03 AM
  • Wed, Feb. 17, 8:02 AM
    | Wed, Feb. 17, 8:02 AM
  • Nov. 12, 2015, 4:50 PM
    • Alcobra (NASDAQ:ADHD): Q3 EPS of -$0.20 beats by $0.11.
    | Nov. 12, 2015, 4:50 PM
  • Aug. 13, 2015, 10:14 AM
    • Alcobra (ADHD +5.1%) Q2 results: Revenues: $0; R&D Expense: $3.7M (-37.3%); SG&A: $1.2M (-7.7%); Net Loss: ($5.1M) (+34.6%); Loss Per Share: ($0.24) (+57.9%); Quick Assets: $41.1M (+89.4%).
    • No guidance given.
    | Aug. 13, 2015, 10:14 AM
  • Aug. 13, 2015, 7:04 AM
    • Alcobra (NASDAQ:ADHD): Q2 EPS of -$0.24 beats by $0.05.
    | Aug. 13, 2015, 7:04 AM
  • May 6, 2015, 10:54 AM
    • Alcobra (ADHD -1.6%) Q1 results: Revenues: $0; R&D Expense: $3.6M (-34.5%); SG&A: $1.3M (-27.8%); Net Loss: ($5.2M) (+33.3%); Loss Per Share: ($0.26) (+54.4%); Quick Assets: $32M (+47.5%).
    • No guidance given.
    | May 6, 2015, 10:54 AM
  • May 6, 2015, 7:33 AM
    • Alcobra (NASDAQ:ADHD): Q1 EPS of -$0.26 beats by $0.03.
    | May 6, 2015, 7:33 AM
  • Feb. 12, 2015, 10:16 AM
    • Alcobra Ltd. (ADHD -3.9%) Q4 results: Revenues: $0; R&D Expense: $4.9M (+6.5%); SG&A: $1.4M (+40.0%); Operating Loss: ($6.8M) (-21.4%); Net Loss: ($6.8M) (-19.3%); Loss Per Share: ($0.50) (-11.1%); CF Ops: ($7.7M) (-60.4%).
    • FY2014 results: Revenues: $0; R&D Expense: $25.1M (+253.5%); SG&A: $5.8M (+81.3%); Operating Loss: ($33.1M) (-221.4%); Net Loss: ($32.8M) (-212.4%); Loss Per Share: ($2.40) (-130.8%); Quick Assets: $21.7M (-56.7%); CF Ops: ($28.3M) (-282.4%).
    • No guidance given.
    | Feb. 12, 2015, 10:16 AM
  • Feb. 12, 2015, 7:44 AM
    • Alcobra (NASDAQ:ADHD): Q4 EPS of -$0.50 beats by $0.10.
    | Feb. 12, 2015, 7:44 AM
  • Nov. 17, 2014, 7:20 AM
    • Alcobra Ltd. (ADHD +1.7%) Q3 results: Revenues: $0; R&D Expense: $8.8M (+319.0%); G&A: $1.3M (+18.2%); Net Loss: ($10.5M) (-238.7%); Loss Per Share: ($0.77) (-175.0%); Quick Assets: $29.4M (-41.3%).
    • No guidance given.
    | Nov. 17, 2014, 7:20 AM
  • Nov. 17, 2014, 7:03 AM
    • Alcobra (NASDAQ:ADHD): Q3 EPS of -$0.77 misses by $0.21.
    | Nov. 17, 2014, 7:03 AM
  • Nov. 6, 2014, 11:07 AM
    • Alcobra Ltd. (ADHD) will report Q3 results on November 17 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.56) per share.
    | Nov. 6, 2014, 11:07 AM
  • Aug. 11, 2014, 1:06 PM
    • Alcobra Ltd. (ADHD +1.8%) Q2 results: Revenues: $0; Net Loss: ($7.8M) (-481.0%); Loss Per Share: ($0.57) (-280.0%); Quick Assets: $38.9M (-22.4%); Cash Burn: ($5.5M) (-999%).
    • No financial guidance given.
    | Aug. 11, 2014, 1:06 PM
Company Description
Alcobra Ltd. engages in the development and commercialization of proprietary pharmaceutical products for the treatment of central nervous system disorders and cognitive dysfunctions. Its proprietary oral drug candidate, Metadoxine Extended Release, to treat Attention Deficit Hyperactivity... More
Sector: Healthcare
Industry: Drug Related Products
Country: Israel